# doravirine, islatravir (doravirine, islatravir) by Patheon Pharmaceuticals Inc.: new drug for further processing listing

**Launch Signal Score:** 15/100

| Field | Value |
|---|---|
| Generic name | doravirine, islatravir |
| NDC | 67651-0416 |
| Labeler | Patheon Pharmaceuticals Inc. |
| Product type | DRUG FOR FURTHER PROCESSING |
| Approval pathway | DRUG FOR FURTHER PROCESSING |
| Dosage form | TABLET, FILM COATED |
| Active ingredients | DORAVIRINE 100 mg/1; ISLATRAVIR ANHYDROUS .25 mg/1 |
| Marketing start | 2026-07-13 |
| Package configurations | 1 |

## Why this score


Source: U.S. FDA National Drug Code (NDC) Directory via openFDA (https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=67651-0416). Last refreshed: 2026-11-04T18:12:05.743Z.
Listing data comes from the FDA NDC directory via openFDA; a listing is not an FDA approval or endorsement and may be updated or withdrawn. Informational only; not medical advice.